{"id":2450,"date":"2016-07-06T13:44:13","date_gmt":"2016-07-06T17:44:13","guid":{"rendered":"https:\/\/www.bumc.bu.edu\/crro\/?page_id=2450"},"modified":"2023-06-07T12:16:32","modified_gmt":"2023-06-07T16:16:32","slug":"sponsor-investigator-training","status":"publish","type":"page","link":"https:\/\/www.bumc.bu.edu\/crro\/training-education\/sponsor-investigator-training\/","title":{"rendered":"Sponsor-Investigator Training"},"content":{"rendered":"<p><span style=\"font-weight: 400;\">Offered on an as-requested basis, this training is required for Principal Investigators who are also taking on the role of Sponsor for an FDA-regulated drug or device study per <\/span><a href=\"https:\/\/www.bumc.bu.edu\/ohra\/hrpp-policies\/hrpp-policies-procedures\/#6.2.3.1\"><span style=\"font-weight: 400;\">HRPP Policy 6.2.3.1<\/span><\/a><span style=\"font-weight: 400;\">. A sponsor is an individual who holds an IND (Investigational New Drug) or IDE (Investigational Device Exemption) and is responsible for the initiation, conduct, and overall oversight of the clinical trial.\u00a0<\/span><\/p>\n<p><span style=\"font-weight: 400;\">Sponsor-Investigator training is held upon request and is one 2-hour session. While this training is required for the PI serving as an Sponsor-Investigator, any member of the research team can attend at the PI\u2019s discretion.\u00a0<\/span><\/p>\n<p><span style=\"font-weight: 400;\">Please <\/span><a href=\"mailto:crro@bu.edu\"><span style=\"font-weight: 400;\">contact us<\/span><\/a><span style=\"font-weight: 400;\"> to schedule the Sponsor-Investigator Training. Note that training is required to be completed prior to IRB approval of research. We recommend that the training request be submitted to us at the same time as IRB submission to ensure completion prior to study approval.\u00a0<\/span><\/p>\n<p><span style=\"font-weight: 400;\">It is also recommended that all Sponsor-Investigators complete <\/span><a href=\"https:\/\/www.bumc.bu.edu\/crro\/training-education\/pi-role-training\/\"><span style=\"font-weight: 400;\">PI Training<\/span><\/a><span style=\"font-weight: 400;\"> to gain a more fundamental understanding of the oversight responsibilities any Principal Investigator has. This is not required as a prerequisite for requesting Sponsor-Investigator training, only a recommendation.\u00a0<\/span><\/p>\n<h5 style=\"text-decoration: underline; font-size: 16px; margin-bottom: 2px;\"><b>Additional Resources for Sponsor-Investigators<\/b><\/h5>\n<ul>\n<li style=\"font-weight: 400;\" aria-level=\"1\"><span style=\"font-weight: 400;\">Institutional Resources<\/span>\n<ul>\n<li style=\"font-weight: 400;\" aria-level=\"2\"><a href=\"https:\/\/www.bumc.bu.edu\/ohra\/hrpp-policies\/hrpp-policies-procedures\/#12.1\"><span style=\"font-weight: 400;\">HRRP Policy 12.1 Investigational New Drug (IND) Application<\/span><\/a><\/li>\n<li style=\"font-weight: 400;\" aria-level=\"2\"><a href=\"https:\/\/www.bumc.bu.edu\/ohra\/hrpp-policies\/hrpp-policies-procedures\/#12.2\"><span style=\"font-weight: 400;\">HRPP Policy 12.2 Investigational Device Exemption (IDE)<\/span><\/a><span style=\"font-weight: 400;\"><\/span><\/li>\n<\/ul>\n<\/li>\n<li style=\"font-weight: 400;\" aria-level=\"2\"><span style=\"font-weight: 400;\">FDA Resources <\/span><span style=\"font-weight: 400;\">\u00a0<\/span>\n<ul>\n<li style=\"font-weight: 400;\" aria-level=\"2\"><a href=\"https:\/\/www.fda.gov\/drugs\/types-applications\/investigational-new-drug-ind-application\"><span style=\"font-weight: 400;\">Investigational New Drug Application<\/span><\/a>\n<ul>\n<li style=\"font-weight: 400;\" aria-level=\"3\"><a href=\"https:\/\/www.accessdata.fda.gov\/scripts\/cdrh\/cfdocs\/cfcfr\/CFRsearch.cfm?CFRPart=312\"><span style=\"font-weight: 400;\">21 CFR 312<\/span><\/a><span style=\"font-weight: 400;\"> Investigational New Drug Application Regulations<\/span><\/li>\n<\/ul>\n<\/li>\n<li style=\"font-weight: 400;\" aria-level=\"2\"><a href=\"https:\/\/www.fda.gov\/medical-devices\/premarket-submissions-selecting-and-preparing-correct-submission\/investigational-device-exemption-ide\"><span style=\"font-weight: 400;\">Investigational Device Exemption<\/span><\/a>\n<ul>\n<li style=\"font-weight: 400;\" aria-level=\"3\"><a href=\"https:\/\/www.accessdata.fda.gov\/scripts\/cdrh\/cfdocs\/cfCFR\/CFRSearch.cfm?CFRPart=812\"><span style=\"font-weight: 400;\">21 CFR 812<\/span><\/a><span style=\"font-weight: 400;\"> Investigational Device Exemptions Regulations<\/span><\/li>\n<\/ul>\n<\/li>\n<li style=\"font-weight: 400;\" aria-level=\"2\"><a href=\"https:\/\/www.accessdata.fda.gov\/scripts\/cdrh\/cfdocs\/cfcfr\/CFRSearch.cfm?CFRPart=50\"><span style=\"font-weight: 400;\">21 CFR 50<\/span><\/a><span style=\"font-weight: 400;\"> Protection of Human Subjects Regulations<\/span><\/li>\n<li style=\"font-weight: 400;\" aria-level=\"2\"><span style=\"font-weight: 400;\">FDA Guidance Documents and Information Sheets: <\/span><i><span style=\"font-weight: 400;\">note that many of these documents are considered \u201cdrafts\u201d by the FDA and contain \u201cnon-binding recommendations\u201d. These guidance documents still can be used to guide investigators in complying with requirements despite their draft designation.<\/span><\/i>\n<ul>\n<li style=\"font-weight: 400;\" aria-level=\"3\"><a href=\"https:\/\/www.fda.gov\/media\/77765\/download\"><span style=\"font-weight: 400;\">Investigator Responsibilities \u2013 Protecting the Rights, Safety and Welfare of Study Subjects<\/span><\/a><\/li>\n<li style=\"font-weight: 400;\" aria-level=\"3\"><a href=\"https:\/\/www.fda.gov\/media\/152530\/download\"><span style=\"font-weight: 400;\">Investigator Responsibilities \u2013 Safety Reporting for Investigational Drugs and Devices<\/span><\/a><\/li>\n<li style=\"font-weight: 400;\" aria-level=\"3\"><a href=\"https:\/\/www.fda.gov\/media\/116754\/download\"><span style=\"font-weight: 400;\">Oversight of Clinical Investigations \u2013 A Risk-Based Approach to Monitoring<\/span><\/a><\/li>\n<li style=\"font-weight: 400;\" aria-level=\"3\"><a href=\"https:\/\/www.fda.gov\/media\/148810\/download\"><span style=\"font-weight: 400;\">Frequently Asked Questions Statement of Investigator on the Form FDA 1572<\/span><\/a><\/li>\n<li style=\"font-weight: 400;\" aria-level=\"3\"><a href=\"https:\/\/www.fda.gov\/media\/75459\/download\"><span style=\"font-weight: 400;\">Significant Risk and Nonsignificant Risk Medical Device Studies<\/span><\/a><\/li>\n<li style=\"font-weight: 400;\" aria-level=\"3\"><a href=\"https:\/\/www.fda.gov\/media\/114034\/download\"><span style=\"font-weight: 400;\">Requests for Feedback and Meetings for Medical Device Submissions: The Q-Submission Program<\/span><\/a><\/li>\n<li style=\"font-weight: 400;\" aria-level=\"3\"><a href=\"https:\/\/www.fda.gov\/media\/72267\/download\"><span style=\"font-weight: 400;\">Adverse Event Reporting to IRBs \u2013 Improving Human Subject Protection<\/span><\/a><\/li>\n<li style=\"font-weight: 400;\" aria-level=\"3\"><a href=\"https:\/\/www.fda.gov\/media\/79386\/download\"><span style=\"font-weight: 400;\">Investigational New Drug Applications (INDs) &#8212; Determining Whether Human Research Studies Can Be Conducted Without an IND<\/span><\/a><\/li>\n<\/ul>\n<\/li>\n<\/ul>\n<\/li>\n<\/ul>\n<hr \/>\n<p><i><span>Questions about any of the above information? <\/span><\/i><a href=\"mailto:crro@bu.edu\"><i><span>Contact us!<\/span><\/i><\/a><\/p>\n<ul><\/ul>\n<ul><\/ul>\n","protected":false},"excerpt":{"rendered":"<p>Offered on an as-requested basis, this training is required for Principal Investigators who are also taking on the role of Sponsor for an FDA-regulated drug or device study per HRPP Policy 6.2.3.1. A sponsor is an individual who holds an IND (Investigational New Drug) or IDE (Investigational Device Exemption) and is responsible for the initiation, [&hellip;]<\/p>\n","protected":false},"author":1250,"featured_media":0,"parent":2445,"menu_order":8,"comment_status":"closed","ping_status":"closed","template":"","meta":[],"_links":{"self":[{"href":"https:\/\/www.bumc.bu.edu\/crro\/wp-json\/wp\/v2\/pages\/2450"}],"collection":[{"href":"https:\/\/www.bumc.bu.edu\/crro\/wp-json\/wp\/v2\/pages"}],"about":[{"href":"https:\/\/www.bumc.bu.edu\/crro\/wp-json\/wp\/v2\/types\/page"}],"author":[{"embeddable":true,"href":"https:\/\/www.bumc.bu.edu\/crro\/wp-json\/wp\/v2\/users\/1250"}],"replies":[{"embeddable":true,"href":"https:\/\/www.bumc.bu.edu\/crro\/wp-json\/wp\/v2\/comments?post=2450"}],"version-history":[{"count":13,"href":"https:\/\/www.bumc.bu.edu\/crro\/wp-json\/wp\/v2\/pages\/2450\/revisions"}],"predecessor-version":[{"id":6197,"href":"https:\/\/www.bumc.bu.edu\/crro\/wp-json\/wp\/v2\/pages\/2450\/revisions\/6197"}],"up":[{"embeddable":true,"href":"https:\/\/www.bumc.bu.edu\/crro\/wp-json\/wp\/v2\/pages\/2445"}],"wp:attachment":[{"href":"https:\/\/www.bumc.bu.edu\/crro\/wp-json\/wp\/v2\/media?parent=2450"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}